| Kaitlyn Phelps, | |
|
809 82nd Pkwy, Myrtle Beach, SC 29572-4607 | |
| (843) 692-1752 | |
| Not Available |
| Full Name | Kaitlyn Phelps |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 5 Years |
| Location | 809 82nd Pkwy, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083174825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MDO.82265 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand Strand Regional Medical Center | Myrtle beach, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acs Primary Care Physicians - Southeast Pc | 5193620714 | 323 |
News Archive
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new biomarker that could be used to provide earlier diagnosis for a life-limiting lung condition has been identified by researchers at the University of Bradford.
The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.'s facility in Mohali, India.
Scarring has been shown to have a significant impact on patients' lives. As well as the physical burden associated with skin scarring, psychological strains can also negatively affect the quality of life for patients, with the majority (56%) considering themselves to be ‘abnormal' due to their scars...
› Verified 2 days ago
| Entity Name | Acs Primary Care Physicians - Southeast Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861430555 PECOS PAC ID: 5193620714 Enrollment ID: O20090401000270 |
News Archive
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new biomarker that could be used to provide earlier diagnosis for a life-limiting lung condition has been identified by researchers at the University of Bradford.
The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.'s facility in Mohali, India.
Scarring has been shown to have a significant impact on patients' lives. As well as the physical burden associated with skin scarring, psychological strains can also negatively affect the quality of life for patients, with the majority (56%) considering themselves to be ‘abnormal' due to their scars...
› Verified 2 days ago
| Entity Name | Mcleod Health Cheraw |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275912974 PECOS PAC ID: 7911228259 Enrollment ID: O20151218002079 |
News Archive
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new biomarker that could be used to provide earlier diagnosis for a life-limiting lung condition has been identified by researchers at the University of Bradford.
The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.'s facility in Mohali, India.
Scarring has been shown to have a significant impact on patients' lives. As well as the physical burden associated with skin scarring, psychological strains can also negatively affect the quality of life for patients, with the majority (56%) considering themselves to be ‘abnormal' due to their scars...
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kaitlyn Phelps, 147 Village Center Blvd Unit 4314, Myrtle Beach, SC 29579-5613 Ph: () - | Kaitlyn Phelps, 809 82nd Pkwy, Myrtle Beach, SC 29572-4607 Ph: (843) 692-1752 |
News Archive
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new biomarker that could be used to provide earlier diagnosis for a life-limiting lung condition has been identified by researchers at the University of Bradford.
The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.'s facility in Mohali, India.
Scarring has been shown to have a significant impact on patients' lives. As well as the physical burden associated with skin scarring, psychological strains can also negatively affect the quality of life for patients, with the majority (56%) considering themselves to be ‘abnormal' due to their scars...
› Verified 2 days ago
Benjamin Tyler Mckinney, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Dr. Michael Coletta, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Dr. Edward W King, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2102 Cromley Cir Ste A, Myrtle Beach, SC 29577 Phone: 843-999-0064 | |
Daniel M Mcnabb, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Carolina Health Specialists 4615 Oleander Dr, Suite 201-a, Myrtle Beach, SC 29577 Phone: 843-449-9559 | |
Dalal A Akoury, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4710 Oleander Drive, Myrtle Beach, SC 29577 Phone: 843-213-1480 Fax: 843-712-1973 | |
Charles E. Tarbert, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-497-5929 Fax: 843-497-6601 |